Crescent Biopharma (CBIO) Other Non-Current Assets (2015 - 2026)

Crescent Biopharma (CBIO) has 12 years of Other Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (changed N/A YoY), and the FY2025 annual result was $107000.0, down 86.84% from the prior year.
• Other Non-Current Assets climbed to $1.2 million in Q1 2026 per CBIO's latest filing, from $107000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $2.2 million in Q1 2022 and troughed at $50000.0 in Q4 2022.
• A 5-year average of $451067.7 and a median of $122052.5 in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets surged 4145.81% in 2022, then sank 97.64% in 2023.
• A 5-year view of Other Non-Current Assets shows it stood at $50000.0 in 2022, then jumped by 208.35% to $154176.0 in 2023, then surged by 427.32% to $813000.0 in 2024, then slumped by 86.84% to $107000.0 in 2025, then soared by 983.18% to $1.2 million in 2026.
• Business Quant data shows CBIO's Other Non-Current Assets at $1.2 million in Q1 2026, $107000.0 in Q4 2025, and $1.3 million in Q3 2025.